10x Genomics, Inc. — Director's Dealing 2021

Dec 31, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-12-28

Reporting Person: Saxonov Serge (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-28	Class A Common Stock	M	56363	$1.20	Acquired	934218	Direct
2021-12-13	Class A Common Stock	G	360	$0.00	Disposed	4138	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-28	Stock Option (right to buy)	$1.20	M	56363	Disposed	2027-10-18	Class A Common Stock (56363)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	89960	Indirect

Footnotes

F1: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

F2: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F3: This option, originally for 300,000 shares, of which 247,465 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.